BDTX-189: A MasterKey Inhibitor of EGFR and HER2 Exon 20 Insertion Mutations and Allosteric HER2 Mutations

Time: 12:00 pm
day: Day One


• The role of Black Diamond’s proprietary MAP platform for the identification and validation of allosteric EGFR and HER2 oncogenic driver mutations, including Exon 20 insertion mutations
• Overview of the profile of BDTX-189, including a presentation of preclinical pharmacokinetic, safety, and anti-tumor activity data
• The ongoing MasterKey-01 trial, a Phase 1/2 clinical trial designed to evaluate BDTX-189 for the treatment of patients with solid tumors with a range of allosteric EGFR and HER2 mutations